This meeting has been designed to meet the educational needs of hematologists, oncologist’s, general practitioners in oncology and other health care providers involved in the management of patients with lymphoproliferative and plasma cell disorders.

Learning Objectives

Course Overview: CCOLD Main Sesions

At the completion of the meeting, attendees should be able to:

1. Apply clinical practice guidelines for CLL, NHL and Myeloma
2. Describe advances in understanding biologic heterogeneity of lymphoproliferative disorders (LPD)
3. Describe new WHO classification for LPD and its impact on management
4. Describe new targets for treatment of LPD
5. Apply latest research to optimize management of patients with LPD
6. Describe specific survivorship issues for patients with LPD including fertility and cardiovascular complications
7. Summarize latest information released at ASH, ASCO, Lugano and other international meetings